Nurse practitioner scope of practice and patient harm: Evidence from medical malpractice payouts and adverse action reports
Journal of Policy Analysis and Management · 2024-03 · 43 (2) · 420-445
DOI: 10.1002/pam.22507 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Policy Analysis and Management, online erschienen am 17.07.2023. Verfasst von Sara Markowitz und 1 weiteren Autor:innen. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 49 Literaturangaben.
Themen: Akademisierung der Pflege
Abstract (Originalsprache)
Many states have recently changed their scope of practice laws and granted full practice authority to nurse practitioners, allowing them to practice without oversight from physicians. Physician groups have argued against this change, citing patient safety concerns. In this paper, we use a ratio‐in‐ratio approach to evaluate whether the transition to full practice authority results in harm to patients as proxied by malpractice payouts and adverse action reports against nurse practitioners. We find no evidence of such harm, and instead find that physicians may benefit from the law change in terms of reduced paid malpractice cases against them.
Zitieren
APA
Markowitz, S., & Smith, A. J. D. (2024). Nurse practitioner scope of practice and patient harm: Evidence from medical malpractice payouts and adverse action reports. Journal of Policy Analysis and Management, 43(2), 420-445. https://doi.org/10.1002/pam.22507
Vancouver
Markowitz S, Smith AJD. Nurse practitioner scope of practice and patient harm: Evidence from medical malpractice payouts and adverse action reports. Journal of Policy Analysis and Management. 2024;43(2):420-445. doi:10.1002/pam.22507
BibTeX
@article{Markowitz2024,
author = {Markowitz, Sara and Smith, Andrew J. D.},
title = {Nurse practitioner scope of practice and patient harm: Evidence from medical malpractice payouts and adverse action reports},
journal = {Journal of Policy Analysis and Management},
year = {2024},
volume = {43},
number = {2},
pages = {420--445},
doi = {10.1002/pam.22507}
}
EUVIMED